Jagsonpal Pharmaceuticals Limited provided earnings guidance for the fiscal year 2022. The company expects strong business performance during this fiscal and expect significant momentum in this fiscal on the back of new launches and better product mix. On a consolidated basis, the company expects a revenue growth of 28-30% in Fiscal Year 22 over Fiscal Year 21 and aspire to be in the 22 to 24% EBITDA margins range, barring unforeseen circumstances.